PT  - JOURNAL ARTICLE
AU  - Kageyama, Takahiro
AU  - Ikeda, Kei
AU  - Tanaka, Shigeru
AU  - Taniguchi, Toshibumi
AU  - Igari, Hidetoshi
AU  - Onouchi, Yoshihiro
AU  - Kaneda, Atsushi
AU  - Matsushita, Kazuyuki
AU  - Hanaoka, Hideki
AU  - Nakada, Taka-Aki
AU  - Ohtori, Seiji
AU  - Yoshino, Ichiro
AU  - Matsubara, Hisahiro
AU  - Nakayama, Toshinori
AU  - Yokote, Koutaro
AU  - Nakajima, Hiroshi
TI  - Antibody responses to BNT162b2 mRNA COVID-19 vaccine in 2,015 healthcare workers in a single tertiary referral hospital in Japan
AID  - 10.1101/2021.06.01.21258188
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.01.21258188
4099  - http://medrxiv.org/content/early/2021/06/04/2021.06.01.21258188.short
4100  - http://medrxiv.org/content/early/2021/06/04/2021.06.01.21258188.full
AB  - We measured antibody responses in 2,015 healthcare workers who were receiving 2 doses of BNT162b2 mRNA vaccine against SARS-CoV-2. The vast majority (99.9%) had either seroconversion or a substantial increase in antibody titer. A multivariate linear regression model identified predictive factors for antibody responses which may have clinical implications.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study procedures for sample collection and those for analyses were approved by Chiba University Ethics Committee on February 24th, 2021 (No. HS202101-03) and April 21st, 2021 (No. HS202104-01), respectivelyFunding StatementThis study was supported by a donation to Chiba University Hospital and the Future Medicine Founds at Chiba University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study procedures for sample collection and those for analyses were approved by Chiba University Ethics Committee on February 24th, 2021 (No. HS202101-03) and April 21st, 2021 (No. HS202104-01), respectively.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available after this manuscript is accepted by Scientific Journal.